CoChat

Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial

Mahmoud, Ramy A., Pandina, Gahan J., Turkoz, Ibrahim, Kosik-Gonzalez, Colette, Canuso, Carla M., Kujawa, Mary J., Gharabawi-Garibaldi, Georges M. · 2007 · Annals of Internal Medicine

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Major depressive disorder has high prevalence, morbidity, and mortality. Inadequate results with antidepressants have prompts addition of a nonstandard treatment (augmentation therapy). OBJECTIVE: To assess whether augmentation therapy with risperidone reduces symptoms and increases response to antidepressant therapy and remission of depression in adults. DESIGN: Multicenter, double-blind, placebo-controlled, randomized trial conducted from 19 October 2004 to 17 November 2005. SETTING: 75 primary care and psychiatric centers. PATIENTS: 274 outpatient adults with major depressive disorder that was suboptimally responsive to antidepressant therapy. INTERVENTION: After a 4-week run-in period to ensure insufficient response to standard antidepressants, patients were randomly assigned to receive risperidone, 1 mg/d, or placebo for 6 weeks. After 4 weeks, the dosage of risperidone was increased to 2 mg/d in some cases. MEASUREMENTS: Symptoms were measured by using the 17-item Hamilton Rating Scale for Depression (HRSD-17). Other outcomes were response to therapy, remission of depression, and various clinician- and patient-rated assessments. RESULTS: Of the intention-to-treat population (268 patients), 81% (111 of 137) who received risperidone and 87.8% (115 of 131) who received placebo completed 6 weeks of double-blind treatment. Mean (+/-SE) HRSD-17 scores improved more in the risperidone augmentation group than in the placebo group (13.4 +/- 0.54 vs. 16.2 +/- 0.53; difference, -2.8 +/- 0.72 [95% CI, -4.2 to -1.4]; P <0.001). More risperidone recipients than placebo recipients experienced remission of depression (24.5% [26 of 106] vs. 10.7% [12 of 112]; P = 0.004) and had a response (46.2% [49 of 106] vs. 29.5% [33 of 112]; P = 0.004). Headache (8.8% of risperidone recipients vs. 14.5% of placebo recipients), somnolence (5.1% vs. 1.5%), and dry mouth (5.1% vs. 0.8%) were the most frequently reported adverse events. LIMITATIONS: Patients were receiving many different antidepressants, and the duration of augmentation therapy was limited. CONCLUSION: Risperidone augmentation produced a statistically significant mean reduction in depression symptoms, substantially increased remission and response, and improved other patient- and clinician-rated measures. ClinicalTrials.gov registration number: NCT00095134.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-147-9-200711060-00003

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 42 references

Research works printed but not linked: 10

  1. 10.1001/archpsyc.56.8.763 · doi:10.1001/archpsyc.56.8.763
  2. Blier P, 2001, J Clin Psychiatry, 62, 37
  3. Blier P, 2001, J Psychiatry Neurosci, S3
  4. Zarate CA, 1996, J Clin Psychiatry, 57, 67
  5. Joffe RT, 1996, J Clin Psychiatry, 57, 114
  6. 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
  7. Nasr SJ, 1984, J Clin Psychiatry, 45, 167
  8. Hamilton M, 1960, J Neurol Neurosurg Psychiatry, 163, 28
  9. Kalali AH, 2002, Int J Neuropsychopharma, 5, S147
  10. Endicott J, 1993, Psychopharmacol Bull, 29, 321

Cited by

See all 140

Metadata

Authors
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M.
Affiliations
  • Janssen Scientific Affairs (United States) (US)
  • From Ortho-McNeil Janssen Scientific Affairs, Titusville, New Jersey.
Venue
Annals of Internal Medicine
Published
2007-11-06
Volume
147
Issue
9
Pages
593-602
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2070007822
Cited by
140
References
44
Citations by year
2026: 6 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 4 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 8 · 2014: 13 · 2013: 14 · 2012: 4
FWCI
9.62
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
risperidone, major depressive disorder, treatment-resistant depression, augmentation therapy, antidepressant non-response, atypical depression, depression remission, antidepressant response, antipsychotic augmentation, adverse effects, headache, sleepiness, primary care depression treatment, atypical antipsychotics, mood stabilizers, lithium, valproic acid, carbamazepine
MeSH terms
Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Quality of Life, Remission Induction, Antipsychotic Agents, Risperidone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-147-9-200711060-00003
The paper
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007). Risperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-9-200711060-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.